Esbriet
NICE rejects expanded treatment indication for Roche’s Esbriet
September 19, 2016Sales and Marketing Esbriet, NICE, Roche, rejection
NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …
Boehringer launches IPF initiatives
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev
Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
Roche beats estimates with strong 2015 sales
January 28, 2016Medical Communications, Sales and Marketing Esbriet, Herceptin, Roche, avastin
Roche reported full-year financial results today, beating analysts’ estimates, with the Swiss drugmaker announcing Group sales increases for 2015 in …
Roche says Esbriet shown to extend lives of IPF patients
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis
Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …
Roche to present new Esbriet data at ERS Congress 2015
September 21, 2015Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone
Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …
Boehringer widens IPF drug’s reach
May 18, 2015Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev
Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
CHMP nods several drugs through
November 24, 2014Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev
Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …
Growing IPF drugs market evident at ERS Congress
November 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev
Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
InterMune stock jumps on suitor claims
August 14, 2014Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune
Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …
Shortlist announced for best new pharma product
June 24, 2014Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro
Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
